Fuji Pharma Co Ltd (4554) Q1 2024 earnings summary

Executive summary

• Q1 FY9/24 net sales rose 7.5% YoY to ¥10,746 million; operating profit was a ¥140 million loss and ordinary profit a ¥96 million loss, while profit attributable to owners of parent rose 145.9% to ¥2,739 million.

• Net profit growth reflected ¥3,953 million of extraordinary income, including gains on investment securities and donation income.

Financial highlights

• Gross profit fell to ¥3,552 million from ¥4,034 million; SG&A expenses increased to ¥3,692 million from ¥2,843 million.

• Basic EPS was ¥112.73 versus ¥45.88 a year earlier; comprehensive income was ¥1,266 million, down from ¥3,094 million, reflecting ¥1,473 million of other comprehensive losses, including securities valuation losses.

Outlook and guidance

• FY9/24 guidance was unchanged: net sales ¥48,926 million, operating profit ¥4,907 million, ordinary profit ¥5,562 million and net profit ¥6,185 million; Q1 net sales progress was 22.0% and attributable profit progress was 44.3%.

• Six-month guidance: net sales ¥23,672 million, operating profit ¥2,050 million, ordinary profit ¥2,793 million and net profit ¥4,135 million.